CompletedPHASE1, PHASE2NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
Studying Argininemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aeglea Biotherapeutics
- Principal Investigator
- Josie GaytonAeglea Biotherapeutics, Inc.
- Intervention
- AEB1102(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2016 – 2019
Study locations (9)
- Stanford University School of Medicine, Stanford, California, United States
- University of Florida, Gainesville, Florida, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- UTSW, Dallas, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
- Centro Hospitalar S. Joao, Porto, Portugal
- Great Ormond Street Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02488044 on ClinicalTrials.gov